Pharmaron acquires Xceleron Inc.

January 10th, 2017

Pharmaron acquires Xceleron Inc.

Acquisition expands Pharmaron’s radiolabelled sciences capabilities

 

Beijing, January 10, 2017 __ Pharmaron, a fully integrated contract research organization offering R&D services for the life science industry, today announced the acquisition of Xceleron Inc. Xceleron is a Maryland, US-based globally leading Accelerator Mass Spectrometry (AMS) specialist for life sciences.

The AMS platform developed at Xceleron has unique sensitivity and features that allows identification and analysis of therapeutically and biologically relevant entities, including small molecules to large molecules at low concentrations. With this, Xceleron has supported regulatory filings for dozens of marketed drugs since 1998. The technology has been developed to support discovery of novel biomarkers and potentially new disease-modifying targets.

Xceleron’s use of microtracers and AMS detection technology complements Pharmaron’s existing platforms of radiolabelled compound manufacturing and radiolabelled metabolism operated in the United Kingdom. The combination of AMS and other established analytical technologies at Pharmaron supports early discovery, preclinical and clinical development. This acquisition is part of Pharmaron’s strategy to provide fully integrated, end-to-end R&D services.

Dr. Boliang Lou, Chairman and CEO of Pharmaron commented: “We are pleased to welcome another industry-leading R&D platform to the Pharmaron Group, once again demonstrating our commitment to becoming a global leader in drug R&D services. The addition of Xceleron develops and differentiates our capabilities in translational science and clinical development services, and further strengthens our ability to support our worldwide collaborators and partners with fully integrated pharmaceutical R&D services.”

Dr. Michael Butler, CEO, Xceleron commented: “With the support of our investors, the Xceleron team has worked diligently to create an analytical platform that is now accepted as a valuable component of the contemporary pharmaceutical development tool-box. We are excited to become a part of Pharmaron’s integrated drug research and development platform as it allows for new opportunities to serve our customers arising from the combination of our AMS technology with Pharmaron’s extensive and growing capabilities.”

Commercial details on the transaction are not being disclosed.

About Pharmaron

Pharmaron is a private, premier R&D service provider for the life sciences industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism to chemical & pharmaceutical development. With over 4,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. www.pharmaron.com

About Xceleron

Xceleron, located in Germantown, Maryland, pioneered and developed the robust use of 14C microtracers and AMS analytical technology in pharmaceutical R&D. Since 1998, Xceleron has designed new preclinical and clinical investigations around the unique analytical features of AMS. With increased adoption, Xceleron developed a proprietary approach to ensure analytical robustness at the very low levels of detection compared to complimentary traditional platforms such as LC-MS/MS and Liquid Scintillation Counting. Benefiting from Xceleron’s work, AMS detection is now widely accepted as a valuable analytical tool in the quest for improved efficiency in pharmaceutical R&D.

For more information, please contact:

Ashok Tehim, Sr. VP, Strategy, Tel: +1 201 312 5754, ashok.tehim@pharmaron.com

Ellen Cabral, Director, Global Marketing, Tel: +1 617 901 2216, ellen.cabral@pharmaron.com

康龙化成收购美国Xceleron公司

旨在增强其放射性科学领域的研发服务实力

 

北京,2017110日讯__ 康龙化成今天宣布收购位于美国马里兰州的Xceleron公司。该公司专业提供生命科学领域内的检测分析服务,其核心技术为处于世界领先水平的加速型质谱(AMS)技术。

由Xceleron开发的AMS研发平台,具有技术独特、灵敏度高的特性,可用于鉴定和分析浓度极低的小分子药物和大分子药物。自1998年以来,Xceleron利用此项技术,协助完成了几十个已上市药物的法规性申报工作。该技术已被用于发现新颖生物标志物和潜在的且能影响疾病进程的新靶点。

此次收购将进一步完善康龙化成放射性同位素标记化合物生产及相关药物代谢研发平台,有力提升康龙化成在药物早期研发、临床前及临床开发领域的服务能力。此外,作为公司战略的一部分,本次收购将进一步增强康龙化成全方位药物研发一体化服务平台的建设。

康龙化成董事长兼CEO楼柏良博士指出:“我们竭诚欢迎Xceleron加入康龙化成大家庭。此举再次证明了我们致力于成为全球新药研发服务行业领军企业的决心。Xceleron的加入,将强化我们在转化科学和临床开发领域的优势,进一步提升我们为全球合作伙伴提供全方位药物研发一体化服务的水平。”

Xceleron公司CEO迈克尔.巴特勒博士表示:“在我们投资人的支持下,Xceleron 一直以来,致力于独特分析平台的建设。今天,我们欣喜地看到该检测技术已成为现今医药开发过程中的一个重要分析工具。我们非常高兴成为康龙化成一体化新药研发平台的一部分。 AMS技术和康龙化成新药研发平台的全面整合,将为我们客户提供更优质的服务,并创造更多的合作机会。”

双方并未透露此次交易的商业细节。

关于康龙化成

康龙化成新药技术有限公司(非上市企业),成立于2003年,是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务,帮助伙伴们成功开发新药,降低新药研发成本,提高新药研发效率”。经过多年发展,康龙化成打造了全方位的药物研发一体化平台,贯穿合成与药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、放射标记代谢、工艺研发、GMP生产及制剂研发服务等各个领域,提供包括靶标探索与靶标验证、先导化合物发现,先导化合物优化、临床前候选药物筛选、新药临床前及临床开发和新药申报等一体化研发和开发服务。康龙化成在中国、美国、英国均有运营实体,拥有4000多名员工,一流的人才队伍,高质量的研发服务,获得了业界的广泛认可,与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。详情请访问公司网站:www.pharmaron.com

关于 Xceleron

Xceleron, 位于美国马里兰州日耳曼敦,开创性地将加速型质谱(Accelerator Mass Spectrometry,AMS)技术和14C标记的微量示踪物(14C microtracers)应用于药物研发。自1998以来,利用加速型质谱(AMS)这一独特分析平台, Xceleron设计了新颖的用于临床前和临床开发专题的试验方案。经过不断积累,Xceleron开发了比传统的LC-MS/MS和LSC等分析方法更为可靠的极低浓度分析检测技术,拥有独特的专利技术。得益于Xceleron的出色工作,AMS检测技术已被业界广泛接受,并被认为是提高药物研发效率的一种有价值的分析工具。

详情请联系:

Ashok Tehim博士,高级副总裁,企业战略,Tel: +1 201 312 5754, ashok.tehim@pharmaron.com

Ellen Cabral女士, 全球市场营销总监,Tel: +1 617 901 2216, ellen.cabral@pharmaron.com